Maria Jalbrzikowski,Rebecca A. Hayes,Stephen J. Wood,Dorte Nordholm,Juan H. Zhou,Paolo Fusar-Poli,Peter J. Uhlhaas,Tsutomu Takahashi,Gisela Sugranyes,Yoo Bin Kwak,Daniel H. Mathalon,Naoyuki Katagiri,Christine I. Hooker,Lukasz Smigielski,Tiziano Colibazzi,Esther Via,Jinsong Tang,Shinsuke Koike,Paul E. Rasser,Chantal Michel,Irina Lebedeva,Wenche ten Velden Hegelstad,Camilo de la Fuente-Sandoval,James A. Waltz,Romina Mizrahi,Cheryl M. Corcoran,Franz Resch,Christian K. Tamnes,Shalaila S. Haas,Imke L. J. Lemmers-Jansen,Ingrid Agartz,Paul Allen,G. Paul Amminger,Ole A. Andreassen,Kimberley Atkinson,Peter Bachman,Inmaculada Baeza,Helen Baldwin,Cali F. Bartholomeusz,Stefan Borgwardt,Sabrina Catalano,Michael W. L. Chee,Xiaogang Chen,Kang Ik K. Cho,Rebecca E. Cooper,Vanessa L. Cropley,Montserrat Dolz,Bjorn H. Ebdrup,Adriana Fortea,Louise Birkedal Glenthoj,Birte Y. Glenthoj,Lieuwe de Haan,Holly K. Hamilton,Mathew A. Harris,Kristen M. Haut,Ying He,Karsten Heekeren,Andreas Heinz,Daniela Hubl,Wu Jeong Hwang,Michael Kaess,Kiyoto Kasai,Minah Kim,Jochen Kindler,Mallory J. Klaunig,Alex Koppel,Tina D. Kristensen,Jun Soo Kwon,Stephen M. Lawrie,Jimmy Lee,Pablo Leon-Ortiz,Ashleigh Lin,Rachel L. Loewy,Xiaoqian Ma,Patrick McGorry,Philip McGuire,Masafumi Mizuno,Paul Moller,Tomas Moncada-Habib,Daniel Munoz-Samons,Barnaby Nelson,Takahiro Nemoto,Merete Nordentoft,Maria A. Omelchenko,Ketil Oppedal,Lijun Ouyang,Christos Pantelis,Jose C. Pariente,Jayachandra M. Raghava,Francisco Reyes-Madrigal,Brian J. Roach,Jan I. Rossberg,Wulf Rossler,Dean F. Salisbury,Daiki Sasabayashi,Ulrich Schall,Jason Schiffman,Florian Schlagenhauf,Andre Schmidt,Mikkel E. Sorensen,Michio Suzuki,Anastasia Theodoridou,Alexander S. Tomyshev,Jordina Tor,Tor G. Vaernes,Dennis Velakoulis,Gloria D. Venegoni,Sophia Vinogradov,Christina Wenneberg,Lars T. Westlye,Hidenori Yamasue,Liu Yuan,Alison R. Yung,Therese A. M. J. van Amelsvoort,Jessica A. Turner,Theo G. M. van Erp,Paul M. Thompson,Dennis Hernaus

Abstract:Importance:The ENIGMA clinical high risk (CHR) for psychosis initiative, the largest pooled neuroimaging sample of individuals at CHR to date, aims to discover robust neurobiological markers of psychosis risk.Objective:To investigate baseline structural neuroimaging differences between individuals at CHR and healthy controls as well as between participants at CHR who later developed a psychotic disorder (CHR-PS+) and those who did not (CHR-PS-).Design, Setting, and Participants:In this case-control study, baseline T1-weighted magnetic resonance imaging (MRI) data were pooled from 31 international sites participating in the ENIGMA Clinical High Risk for Psychosis Working Group. CHR status was assessed using the Comprehensive Assessment of At-Risk Mental States or Structured Interview for Prodromal Syndromes. MRI scans were processed using harmonized protocols and analyzed within a mega-analysis and meta-analysis framework from January to October 2020.Main Outcomes and Measures:Measures of regional cortical thickness (CT), surface area, and subcortical volumes were extracted from T1-weighted MRI scans. Independent variables were group (CHR group vs control group) and conversion status (CHR-PS+ group vs CHR-PS- group vs control group).Results:Of the 3169 included participants, 1428 (45.1%) were female, and the mean (SD; range) age was 21.1 (4.9; 9.5-39.9) years. This study included 1792 individuals at CHR and 1377 healthy controls. Using longitudinal clinical information, 253 in the CHR-PS+ group, 1234 in the CHR-PS- group, and 305 at CHR without follow-up data were identified. Compared with healthy controls, individuals at CHR exhibited widespread lower CT measures (mean [range] Cohen d = -0.13 [-0.17 to -0.09]), but not surface area or subcortical volume. Lower CT measures in the fusiform, superior temporal, and paracentral regions were associated with psychosis conversion (mean Cohen d = -0.22; 95% CI, -0.35 to 0.10). Among healthy controls, compared with those in the CHR-PS+ group, age showed a stronger negative association with left fusiform CT measures (F = 9.8; P < .001; q < .001) and left paracentral CT measures (F = 5.9; P = .005; q = .02). Effect sizes representing lower CT associated with psychosis conversion resembled patterns of CT differences observed in ENIGMA studies of schizophrenia (ρ = 0.35; 95% CI, 0.12 to 0.55; P = .004) and individuals with 22q11.2 microdeletion syndrome and a psychotic disorder diagnosis (ρ = 0.43; 95% CI, 0.20 to 0.61; P = .001).Conclusions and Relevance:This study provides evidence for widespread subtle, lower CT measures in individuals at CHR. The pattern of CT measure differences in those in the CHR-PS+ group was similar to those reported in other large-scale investigations of psychosis. Additionally, a subset of these regions displayed abnormal age associations. Widespread disruptions in CT coupled with abnormal age associations in those at CHR may point to disruptions in postnatal brain developmental processes.

Cortical and subcortical neuroanatomical signatures of schizotypy in 3004 individuals assessed in a worldwide ENIGMA study

Multiscale characterization of cortical signatures in positive and negative schizotypy: A worldwide ENIGMA study

Thinner cortex is associated with psychosis onset in individuals at Clinical High Risk for Developing Psychosis: An ENIGMA Working Group mega-analysis

Association of Structural Magnetic Resonance Imaging Measures with Psychosis Onset in Individuals at Clinical High Risk for Developing Psychosis: an ENIGMA Working Group Mega-analysis.

Neuroanatomical Heterogeneity and Homogeneity in Individuals at Clinical High Risk for Psychosis

Subcortical Brain Volume Abnormalities in 2028 Individuals with Schizophrenia and 2540 Healthy Controls Via the ENIGMA Consortium

Connectome architecture shapes large-scale cortical alterations in schizophrenia: a worldwide ENIGMA study

Prefrontal Cortical Thinning Links to Negative Symptoms in Schizophrenia Via the ENIGMA Consortium.

A meta‐analysis of deep brain structural shape and asymmetry abnormalities in 2,833 individuals with schizophrenia compared with 3,929 healthy volunteers via the ENIGMA Consortium

Cortical morphology in patients with the deficit and non-deficit syndrome of schizophrenia: a worldwide meta- and mega-analyses

Cortical Brain Abnormalities in 4474 Individuals with Schizophrenia and 5098 Control Subjects Via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium.

Schizophrenia Imaging Signatures and Their Associations with Cognition, Psychopathology, and Genetics in the General Population.

O6.3. PATTERNS OF GRAY MATTER ABNORMALITIES IN PATIENTS WITH FIRST-EPISODE AND TREATMENT-NAïVE SCHIZOPHRENIA

Normative Modeling of Brain Morphometry in Clinical High Risk for Psychosis

Large-scale analysis of structural brain asymmetries in schizophrenia via the ENIGMA consortium

Molecular and micro-architectural mapping of gray matter alterations in psychosis

P580. Two Schizophrenia Neuroanatomical Signatures from the PHENOM Consortium and Their Association with Psychopathology, Cognition, and Genetics in the Population-Level Samples

Widespread white matter microstructural differences in schizophrenia across 4322 individuals: results from the ENIGMA Schizophrenia DTI Working Group

Structural brain abnormalities and aggressive behaviour in schizophrenia: Mega-analysis of data from 2095 patients and 2861 healthy controls via the ENIGMA consortium

Two neurostructural subtypes: results of machine learning on brain images from 4,291 individuals with schizophrenia

Neurostructural subgroup in 4291 individuals with schizophrenia identified using the subtype and stage inference algorithm